Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin

• US 20050261182A1
• Filed: 01/31/2005
• Published: 11/24/2005
• Est. Priority Date: 02/02/2001
• Status: Abandoned Application

• Current Assignee: Ortho-McNeil Pharmaceutical Incorporated (Johnson & Johnson)
• Original Assignee: Ortho-McNeil Pharmaceutical Incorporated (Johnson & Johnson)
• Inventors: Plata-Salaman, Carlos R., Smith-Swintosky, Virginia
• Application Number:
  US11/047,420
• Publication Number:
  US 20050261182A1
• Time in Patent Office: Days
• US Class Current: 514/23
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/357 having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• CPC Class Codes: A61K 38/1816 Erythropoietin [EPO]
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

Co-therapy for the treatment of neurological dysfunctions comprising administration of one or more fructopyranose sulfamates and erythropoietin.

Claims

1. A method for treating a neurological dysfunction in a subject in need thereof, comprising co-therapy with a therapeutically effective amount of a fructopyranose sulfamate and erythropoietin;

wherein the amount of the fructopyranose sulfamate and the amount of the erythropoietin are selected to produce a synergistic effect.

2. The method of claim 1 wherein the fructopyranose sulfamate is topiramate.

3. The method of claim 1, wherein the therapeutically effective amount of the fructopyranose sulfamate is from about 10 to 1000 mg.

4. The method of claim 1, wherein the erythropoietin is epoetin alfa.

5. The method of claim 1, wherein the therapeutically effective amount of erythropoietin is from about 1 to 15000 I.U./kg.

6. The method of claim 1, wherein the neurological dysfunction is selected from a group consisting of acute neurodegenerative disorders and chronic neurodegenerative disorders.

7. The method of claim 1, wherein the neurological dysfunction is selected from a group consisting of cerebrovascular insufficiency, focal brain trauma, diffuse brain trauma, spinal cord injury, cerebral ischemia, cerebral infarction, embolic occlusion, thrombotic occlusion, reperfusion following acute ischemia, perinatal hypoxic-ischemic injury, cardiac arrest, intracranial hemorrhage and whiplash shaken infant syndrome.

8. The method of claim 1, wherein the neurological dysfunction is selected from a group consisting of Alzheimer'"'"'s disease, Pick'"'"'s disease, diffuse Lewy body disease, progressive supranuclear palsy (Steel-Richardson syndrome), multi-system degeneration (Shy-Drager syndrome), chronic epileptic conditions associated with neurodegeneration, motor neuron diseases, amyotrophic lateral sclerosis, degenerative ataxias, cortical basal degeneration, ALS-Parkinson'"'"'s-Dementia complex of Guam, subacute sclerosing panencephalitis, Huntington'"'"'s disease, Parkinson'"'"'s disease, synucleinopathies, primary progressive aphasia, striatonigral degeneration, Machado-Joseph disease/spinocerebellar ataxia type 3 degeneration, olivopontocerebellar degeneration, Gilles De La Tourette'"'"'s disease, bulbar palsy, pseudobulbar palsy, spinal muscular atrophy, spinobulbar muscular atrophy (Kennedy'"'"'s disease), multiple sclerosis, primary lateral sclerosis, familial spastic paraplegia, Werdnig-Hoffmann disease, Kugelberg-Welander disease, Tay-Sach'"'"'s disease, Sandhoff disease, familial spastic disease, Wohlfart-Kugelberg-Welander disease, spastic paraparesis, progressive multifocal leukoencephalopathy, familial dysautonomia (Riley-Day syndrome), prion disease, Creutzfeldt-Jakob disease, Gerstmann-Strä

ussler-Scheinker disease, Kuru insomnia and fatal familial insomnia.

9. The method of claim 8, wherein the neurological dysfunction is selected from a group consisting of Alzheimer'"'"'s disease and Parkinson'"'"'s disease.

10. The method of claim 1, wherein the neurological dysfunction is dementia.

11. The method of claim 1, wherein the neurological dysfunction is selected from a group consisting of diminished memory, diminished mental capacity and mental deterioration.

12. The method of claim 1, wherein the neurological dysfunction is selected from a group consisting of neurological and psychiatric manifestations associated with disease or injury.

13. The method of claim 1, wherein the neurological dysfunction is selected from a group consisting of psychiatric and neurological manifestations associated with peripheral disease.

14. The method of claim 1, wherein the neurological dysfunction is selected from a group consisting of plexopathies, neuropathies, and disorders of the cranial nerves.

15. The method of claim 1, wherein the neurological dysfunction is selected from a group consisting of psychiatric and neurological manifestations associated with an acute neurodegenerative disorder.

16. The method of claim 1, wherein the neurological dysfunction is selected from a group consisting of psychiatric and neurological manifestations associated with a chronic neurodegenerative disorder.

17. The method of claim 1, wherein the neurological dysfunction is selected from a group consisting of psychiatric and neurological manifestations resulting from an epileptic condition.

18. The method of claim 1, wherein the neurological dysfunction is selected from a group consisting of psychiatric and neurological manifestations of a post-ictal, a post-seizure or an inter-ictal state.

19. The method of claim 1, wherein the fructopyranose sulfamate is topiramate and the erythropoietin is epoetin alfa.

20-24. -24. (canceled)